@Article{Izdebska2005,
journal="Klinika Oczna / Acta Ophthalmologica Polonica",
issn="0023-2157",
volume="107",
number="2",
year="2005",
title="Lewofloksacyna (Oftaquix) fluorochinolon nowej generacji w zapobieganiu zapalenia wnętrza gałki ocznej po niepowikłanych operacjach zaćmy – badanie Europejskiego Towarzystwo Chirurgów Zaćmy i Chirurgii Refrakcyjnej (European Society of Cataract and Refractive Surgeons – ESCRS)",
abstract="Randomised multi-centre european clinical trial of antibiotic prophylaxis for endophthalmitis following cataract surgery – study has just begun in Poland. Poland is joining one of the largest prospective european clinical study of antibiotic prophylaxis and the largest in ophthalmology – the ESCRS endophthalmitis prophylaxis clinical trial. Up to 35 000 cataract patients are going to be recruited for this randomized, controlled, multi-centre study in 16 centres from 10 european countries. The goal is to reduce the incidence of endophthalmitis after cataract phacoemusification in Europe to less than 0.05% (less than 1 per 2 000 surgeries). The patients will be divided into four groups; different regimes of two antibiotics: cefuroxime injected intra-camerally and levofloxacine eye drops topically will be compared.",
author="Izdebska, Justyna
and Szaflik, Jacek",
pages="344--347",
url="https://www.termedia.pl/Levofloxacin-Oftaquix-a-fluoroquinolone-of-a-new-generation-in-prevention-of-the-postoperative-endophthalmitis-following-uncomplicated-cataract-surgery-the-study-of-the-European-Society-of-Cataract-an,124,49663,1,1.html"
}